title: Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity.
abstract: Circulating levels of the pancreatic beta-cell peptide hormone amylin and the gut peptide PYY[3-36] increase after nutrient ingestion. Both have been implicated as short-term signals of meal termination with anorexigenic and weight-reducing effects. However, their combined effects are unknown. We report that the combination of amylin and PYY[3-36] elicited greater anorexigenic and weight-reducing effects than either peptide alone. In high-fat-fed rats, a single ip injection of amylin (10 microg/kg) plus PYY[3-36] (1000 microg/kg) reduced food intake for 24 h (P < 0.05 vs. vehicle), whereas the anorexigenic effects of either PYY[3-36] or amylin alone began to diminish 6 h after injection. These anorexigenic effects were dissociable from changes in locomotor activity. Subcutaneous infusion of amylin plus PYY[3-36] for 14 d suppressed food intake and body weight to a greater extent than either agent alone in both rat and mouse diet-induced obesity (DIO) models (P < 0.05). In DIO-prone rats, 24-h metabolic rate was maintained despite weight loss, and amylin plus PYY[3-36] (but not monotherapy) increased 24-h fat oxidation (P < 0.05 vs. vehicle). Finally, a 4 x 3 factorial design was used to formally describe the interaction between amylin and PYY[3-36]. DIO-prone rats were treated with amylin (0, 4, 20, and 100 microg/kg.d) and PYY[3-36] (0, 200, 400 microg/kg.d) alone and in combination for 14 d. Statistical analyses revealed that food intake suppression with amylin plus PYY[3-36] treatment was synergistic, whereas body weight reduction was additive. Collectively, these observations highlight the importance of studying peptide hormones in combination and suggest that integrated neurohormonal approaches may hold promise as treatments for obesity.
authors.affiliation: Amylin Pharmaceuticals Inc., 9360 Towne Centre Drive, San Diego, CA 92121, USA. jonathan.roth@amylin.com
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Roth
authors.forename: Todd
authors.initials: T
authors.lastname: Coffey
authors.forename: Carolyn M
authors.initials: CM
authors.lastname: Jodka
authors.forename: Holly
authors.initials: H
authors.lastname: Maier
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Athanacio
authors.forename: Christine M
authors.initials: CM
authors.lastname: Mack
authors.forename: Christian
authors.initials: C
authors.lastname: Weyer
authors.forename: David G
authors.initials: DG
authors.lastname: Parkes
mesh_terms: D000682:Amyloid / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004041:Dietary Fats; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004435:Eating / Q000187:drug effects; D006801:Humans; D058228:Islet Amyloid Polypeptide; D008297:Male; D051379:Mice; D009765:Obesity / Q000139:chemically induced / Q000188:drug therapy*; D010446:Peptide Fragments; D019894:Peptide YY / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D000682:Amyloid; D019440:Anti-Obesity Agents; D004041:Dietary Fats; D058228:Islet Amyloid Polypeptide; D010446:Peptide Fragments; D019894:Peptide YY; C061785:peptide YY (3-36)